Pluri (PLUR) Competitors $4.18 -0.36 (-8.02%) Closing price 02/21/2025 03:24 PM EasternExtended Trading$4.40 +0.23 (+5.48%) As of 02/21/2025 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PLUR vs. RENB, TELO, CRBU, IZTC, MIST, VTYX, VIRI, IFRX, EPRX, and SAVAShould you be buying Pluri stock or one of its competitors? The main competitors of Pluri include Renovaro (RENB), Telomir Pharmaceuticals (TELO), Caribou Biosciences (CRBU), Invizyne Technologies (IZTC), Milestone Pharmaceuticals (MIST), Ventyx Biosciences (VTYX), Virios Therapeutics (VIRI), InflaRx (IFRX), Eupraxia Pharmaceuticals (EPRX), and Cassava Sciences (SAVA). These companies are all part of the "pharmaceutical products" industry. Pluri vs. Renovaro Telomir Pharmaceuticals Caribou Biosciences Invizyne Technologies Milestone Pharmaceuticals Ventyx Biosciences Virios Therapeutics InflaRx Eupraxia Pharmaceuticals Cassava Sciences Renovaro (NASDAQ:RENB) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, community ranking, valuation and profitability. Does the media favor RENB or PLUR? In the previous week, Renovaro had 1 more articles in the media than Pluri. MarketBeat recorded 2 mentions for Renovaro and 1 mentions for Pluri. Renovaro's average media sentiment score of 0.91 beat Pluri's score of 0.00 indicating that Renovaro is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Renovaro 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pluri 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders have more ownership in RENB or PLUR? 71.4% of Renovaro shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 21.7% of Renovaro shares are owned by company insiders. Comparatively, 10.2% of Pluri shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has higher valuation and earnings, RENB or PLUR? Pluri has higher revenue and earnings than Renovaro. Renovaro is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRenovaroN/AN/A-$80.65M-$0.93-0.89Pluri$330K88.58-$20.89M-$5.60-0.75 Which has more risk & volatility, RENB or PLUR? Renovaro has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500. Comparatively, Pluri has a beta of 1.67, indicating that its share price is 67% more volatile than the S&P 500. Does the MarketBeat Community prefer RENB or PLUR? Renovaro and Pluri both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformRenovaroN/AN/APluriN/AN/A Is RENB or PLUR more profitable? Renovaro has a net margin of 0.00% compared to Pluri's net margin of -3,551.49%. Renovaro's return on equity of -61.84% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets RenovaroN/A -61.84% -48.07% Pluri -3,551.49%-2,778.13%-83.61% SummaryRenovaro beats Pluri on 8 of the 12 factors compared between the two stocks. Get Pluri News Delivered to You Automatically Sign up to receive the latest news and ratings for PLUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLUR vs. The Competition Export to ExcelMetricPluriBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.77M$3.11B$5.84B$9.15BDividend YieldN/A1.55%4.75%3.85%P/E Ratio-0.7529.6426.1519.13Price / Sales88.58329.47435.3370.72Price / CashN/A168.8738.0134.83Price / Book-9.943.687.644.62Net Income-$20.89M-$71.72M$3.19B$245.94M7 Day Performance-9.61%-2.50%-2.11%-2.62%1 Month Performance-1.97%-0.32%-0.49%-2.15%1 Year Performance-28.05%-12.32%16.44%12.95% Pluri Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLURPluri0.2095 of 5 stars$4.18-8.0%N/A-30.3%$31.77M$330,000.00-0.75150RENBRenovaro0.7629 of 5 stars$0.81+9.0%N/A-61.1%$128.39MN/A-0.8420Earnings ReportNews CoverageGap UpTELOTelomir Pharmaceuticals2.2879 of 5 stars$4.29+0.5%N/A-54.8%$127.67MN/A-7.401Analyst ForecastNews CoverageCRBUCaribou Biosciences3.1342 of 5 stars$1.35+3.1%$10.33+665.4%-80.8%$122.25M$11.48M-0.82100IZTCInvizyne TechnologiesN/A$19.42+0.7%N/AN/A$121.38MN/A0.00N/AMISTMilestone Pharmaceuticals2.8117 of 5 stars$2.27-0.9%$13.00+472.7%+29.1%$121.06M$1M-2.8030VTYXVentyx Biosciences3.1146 of 5 stars$1.71+1.8%$10.00+484.8%-68.1%$120.92MN/A-0.7230Upcoming EarningsVIRIVirios TherapeuticsN/A$6.13-8.6%$3.00-51.1%+1,411.6%$118.05MN/A-22.705IFRXInflaRx3.5034 of 5 stars$2.00-25.9%$8.00+300.0%+21.9%$117.76M$70,000.00-1.8560Gap DownHigh Trading VolumeEPRXEupraxia Pharmaceuticals3.4164 of 5 stars$3.28+1.2%$9.00+174.4%N/A$116.83MN/A-4.5629Analyst ForecastShort Interest ↓News CoverageHigh Trading VolumeSAVACassava Sciences3.7726 of 5 stars$2.42+1.7%$111.50+4,507.4%-88.5%$116.43MN/A-1.7530Gap Up Related Companies and Tools Related Companies Renovaro Competitors Telomir Pharmaceuticals Competitors Caribou Biosciences Competitors Invizyne Technologies Competitors Milestone Pharmaceuticals Competitors Ventyx Biosciences Competitors Virios Therapeutics Competitors InflaRx Competitors Eupraxia Pharmaceuticals Competitors Cassava Sciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PLUR) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pluri Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pluri With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
